Get startedLog in
    Picture of Novartis AG logo

    NOVN — Novartis AG News Story

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareConservativeLarge CapHigh Flyer
    All News

    Brief: Novartis Delpacibart Braxlosiran Phase I/II Study In Facioscapulohumeral Muscular Dystrophy Meets Primary Biomarker Endpoint

    Picture of Novartis AG logoNovartis AG
    11/06/2026 06:02
    BRIEF-Novartis Delpacibart Braxlosiran Phase I/II Study In Facioscapulohumeral Muscular Dystrophy Meets Primary Biomarker Endpoint
    June 11 (Reuters) - NOVARTIS AG NOVN.S:
    • NOVARTIS DELPACIBART BRAXLOSIRAN (DEL-BRAX) PHASE I/II STUDY IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) MEETS PRIMARY BIOMARKER ENDPOINT
    • NOVARTIS AG - FORTITUDE STUDY MEETS PRIMARY AND KEY SECONDARY ENDPOINTS FOR DEL-BRAX
    • NOVARTIS AG - DEL-BRAX SHOWS POTENTIAL AS FIRST DISEASE-MODIFYING TREATMENT FOR FSHD
    • NOVARTIS AG - TO ENGAGE REGULATORS ON DEL-BRAX PHASE I/II DATA; PHASE III ENROLLING
    • NOVARTIS AG - DEL-BRAX RECEIVES FDA ORPHAN DRUG AND FAST TRACK DESIGNATIONS; IN PHASE III DEVELOPMENT
    Source text: ID:nGNE71RXCP
    Further company coverage: NOVN.S

     (Gdansk Newsroom)
     ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Novartis AG

    See all news